Viet Le, DMSc, PA-C

Learn when cardiac myosin inhibitors suffice and when myectomy or alcohol ablation fits, with shared decisions at expert HCM centers.

MAPLE HCM reveals aficamten beats beta blockers in obstructive HCM, reshaping first-line therapy debates amid insurance hurdles.

Explore how aficamten’s shorter half-life enables faster titration, flexible echo monitoring, and fewer drug interactions—making HCM treatment more patient-friendly and accessible.

When beta blockers fall short in obstructive HCM, explore myosin inhibitors, disopyramide, or septal reduction—and see why patients breathe easier.

When beta blockers fall short in obstructive HCM, explore myosin inhibitors, disopyramide, or septal reduction—and learn why patients breathe easier.

Learn key hypertrophic cardiomyopathy symptoms and how echoes with Valsalva or exercise reveal hidden LVOT obstruction for accurate diagnosis.

Panelists discuss the signs, symptoms, diagnostic delays, and classification of obstructive hypertrophic cardiomyopathy, including how it differs from other forms and its implications for clinical management.

Panelists discuss the challenges and gaps in diagnosing hypertrophic cardiomyopathy, including variability in clinical practice, underdiagnosis, and opportunities to improve detection.

Le discusses the AHA/ACC clinical guidelines for the management of dyslipidemia, highlighting the shifting attitude towards hypertriglyceridemia treatment.

Le discusses the AHA/ACC clinical guidelines for the management of dyslipidemia, highlighting the return of LDL-C target goals for ASCVD prevention.

Le discusses the AHA/ACC clinical guidelines for the management of dyslipidemia, highlighting PREVENT and a renewed focus on Lp(a).

This Heart Failure Awareness Week, revisit recent advancements and scope out the future of heart failure care with HCPLive.

In the final segment, experts discuss how to navigate traditional or cultural foods with patients in the absence of their inclusion in the guidelines.

In part 7 of the discussion, experts reflect on access issues regarding foods recommended in the guidelines.

Part 6 of the discussion takes a closer look at added sugar recommendations from the guidelines and scenarios where individualization may be needed.

In part 5 of the discussion, the panel examines gaps within the pediatric sections of the updated dietary guidelines.

In part 4 of the discussion, experts review notable omissions and oversights in the guidelines, including fiber, whole grains, and plant-based foods.

In part 3 of this discussion, experts break down saturated fat recommendations and why visuals in the guidelines may cause confusion.

In part 2 of the discussion, experts discuss recommendations around protein intake, including controversy and misconceptions.

In the opening segment of this special report, a trio of experts discuss what's new in the 2025-2030 Dietary Guidelines.

GLP-1 receptor agonists revolutionize treatment in cardiology, offering new hope for heart failure and related conditions beyond weight loss.

Explore the critical role of nutrition and pharmacologic therapies in managing hypertriglyceridemia and preventing pancreatitis effectively.

Explore how the latest FDA approvals impact the management of FCS.

Panelists break down the potential role of plozasiran in FCS based on the PALISADE trial.

Understanding severe hypertriglyceridemia is crucial for preventing pancreatitis and managing triglyceride levels effectively.

Discover effective strategies to shorten the diagnostic window for pancreatitis and manage high triglyceride levels in FCS.

Explore the challenges and advancements in managing FCS with expert insights on treatment and patient care.

Le discusses the increased risk of mortality and major adverse cardiovascular events in patients with both PAD and AF.

This conference preview with Viet Le, DMSc, PA-C, for the 2025 AHA Scientific Sessions highlights the top 5 trials to watch.